← All trials
NCT04416048
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- May 30, 2021
- First posted
- Jun 4, 2020
- Last posted
- Jun 4, 2020
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Humboldt UniversityLead sponsor
- German Center for Cardiovascular Research e. V. (DZHK)Collaborator
- BayerCollaborator
- Ludwig Maximilians UniversityOverall official - principal investigator
- Humboldt UniversityReponsible party - principal investigator
- Humboldt UniversityOverall official - principal investigator
- Charité University, Berlin, GermanyOverall official - principal investigator
- J. W. Goethe UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.